Droplet Biosciences has developed a pioneering approach to liquid biopsy by focusing on the lymphatic system, which plays a crucial role in cancer metastasis. Their technology allows for the collection and analysis of lymph-rich surgical drain fluid, providing a novel and non-invasive method to assess recurrence risk in cancer patients. This approach leverages the proximity of lymphatic fluid to the tumor site, enabling a more accurate evaluation of local disease and potential metastasis. By analyzing this fluid, Droplet can detect molecular-level disease and identify positive lymph nodes that may have been overlooked during surgery, thus enhancing the understanding of a patient's cancer status.

The company's liquid biopsy platform offers timely insights that can significantly influence post-operative treatment decisions. By delivering sensitive results immediately after surgery, Droplet enables healthcare teams to assess metastatic risk at a critical juncture, allowing for tailored adjuvant treatment plans. This innovative method addresses the limitations of traditional blood-based ctDNA markers, which often lack the sensitivity and timeliness needed for effective intervention. Overall, Droplet Biosciences is transforming cancer care by providing a deeper understanding of the tumor microenvironment and improving patient outcomes through advanced diagnostic capabilities.

United States

Droplet has pioneered a platform to harvest and profile patient lymph through the routine collection of surgical drain fluid.

Droplet Biosciences

Company Details